Top

Neurological Sciences

Published in:

06-04-2022 | Parkinson's Disease | Original Article

Risk factors for motor complications in female patients with Parkinson’s disease

Authors: Zhirong Wan, Xuemei Wang, Huizi Ma, Zhan Wang, Tao Feng

Published in: Neurological Sciences | Issue 8/2022

Abstract

Objective

To investigate the risk factors of motor complications in female patients with Parkinson’s disease (PD) and the correlation between the occurrence of motor complications and sex hormone levels.

Methods

According to the occurrence and types of motor complications, 103 female PD patients were divided into two groups: patients with or without the wearing-off phenomenon, patients with or without dyskinesia. Binary logistic regression analysis was performed respectively to screen for the risk factors of the wearing-off phenomenon and dyskinesia in female PD patients.

Results

Among 103 female PD patients, 44 (42.72%) had motor complications. Patients with the wearing-off phenomenon and patients with dyskinesia had higher prolactin levels than patients without the wearing-off phenomenon and patients without dyskinesia, respectively. However, the difference was no longer significant when the two groups were corrected for multiple comparisons (P < 0.0028). Multivariate analysis found that younger age at onset and higher Hoehn-Yahr (H&Y) stage were identified as independent risk factors for the wearing-off phenomenon and younger age of onset was an independent risk factor for dyskinesia in female PD patients (P < 0.05).

Conclusion

Female PD patients have a higher incidence of motor complications. Younger age of onset and higher H&Y stage were the risk factors of the wearing-off phenomenon, and younger onset age was the risk factor of dyskinesia in female PD patients. There may be a certain correlation between the occurrence of motor complications and sex hormone levels in female PD patients, which requires further verification.

Torra A, Parent A, Cuadros T, Rodríguez-Galván B, Ruiz-Bronchal E, Ballabio A, Bortolozzi A, Vila M, Bové J (2018) Overexpression of TFEB drives a pleiotropic neurotrophic effect and prevents Parkinson’s disease-related neurodegeneration. Mol Ther 26(6):1552–1567. https://doi.org/10.1016/j.ymthe.2018.02.022CrossRefPubMedPubMedCentral

Akram H, Wu C, Hyam J, Foltynie T, Limousin P, De Vita E, Yousry T, Jahanshahi M, Hariz M, Behrens T, Ashburner J, Zrinzo L (2017) l-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson’s disease. Mov Disord 32(6):874–883. https://doi.org/10.1002/mds.27017CrossRefPubMedPubMedCentral

Romagnolo A, Fabbri M, Merola A, Montanaro E, Palermo S, Martone T, Seresini A, Goldwurm S, Rizzone MG, Lopiano L (2018) Beyond 35 years of Parkinson’s disease: a comprehensive clinical and instrumental assessment. J Neurol 265(9):1989–1997. https://doi.org/10.1007/s00415-018-8955-zCrossRefPubMed

Dali W, Zhengqin S, Rui H, Fucheng Q, Hongxu C, Ping G (2016) Study on motor complications in patients with Parkinson’s disease. Chin J Coal Ind Med 19(12):1693–1696

Huiqing Z, Genliang L, Yanying S, Zhan W (2019) The relationship between endogenous estrogen levels and non-motor symptoms in postmenopausal Parkinson’s disease patients. Chin J Fam Plan 27(08):1083–1086

Yueqi Z, Gang W (2016) Introduction of the new criteria for clinical diagnosis of Parkinson’s disease of the International Movement Disorders Association (2015). J Diagn Concepts Pract 15(02):122–123

Hongwei Q, Wan Ying Hu, Yingying CZ, Na Wu, Jing G, Zhenguo L (2019) Analysis of clinical characteristics of the wearing-off phenomenon in Parkinson’s disease. Chin J Clin Neurosci 27(04):395–404

Guoyong Z, Zhang Yu, Aijuan Y et al (2018) Research progress on the risk factors, diagnosis and treatment of Parkinson’s disease dyskinesia. Chin J Neurol 51(12):1002–1007

Ryu DW, Lee SH, Oh YS, An JY, Park JW, Song IU, Lee KS, Kim JS (2017) Clinical characteristics of Parkinson’s disease developed from essential tremor. J Parkinsons Dis 7(2):369–376. https://doi.org/10.3233/jpd-160992CrossRefPubMed

10.

Maass F, Michalke B, Leha A, Boerger M, Zerr I, Koch JC, Tönges L, Bähr M, Lingor P (2018) Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson’s disease. J Neurochem 145(4):342–351. https://doi.org/10.1111/jnc.14316CrossRefPubMed

11.

Millage B, Vesey E, Finkelstein M, Anheluk M (2017) Effect on gait speed, balance, motor symptom rating, and quality of life in those with stage I Parkinson’s disease utilizing LSVT BIG®. Rehabil Res Pract 2017:9871070. https://doi.org/10.1155/2017/9871070CrossRefPubMedPubMedCentral

12.

Jinli Z (2017) Clinical observation of 37 cases of Parkinson’s disease treated with levodopa/benserazide. Contemp Med 23(04):68–69

13.

Xue B, Yuping J (2017) Treatment of levodopa peak dose dyskinesia in Parkinson’s disease. Chin J Clin Neurosci 25(03):301–305

14.

Jing T, Xiaoguang L (2019) Factors associated with levodopa-induced wearing-off phenomenon in Parkinson’s disease. J Int Neurol Neurosurg 46(04):387–390

15.

Zhirong W, Zhang Yu, Gao Jing Su, Dongning SM, Tao F (2017) Analysis of related factors affecting menstrual period in female Parkinson’s disease patients. J Clin Neurol 30(03):200–203

16.

Yanru Ma, Rui G, Hongyan R (2017) Progress in the treatment of motor complications of Parkinson’s disease. Orient Diet Health Care 4(10):317–317

17.

Kadastik-Eerme L, Taba N, Asser T, Taba P (2017) Factors associated with motor complications in Parkinson’s disease. Brain Behav 7(10):e00837. https://doi.org/10.1002/brb3.837CrossRefPubMedPubMedCentral

18.

Zhang Lu, Yujun P (2017) Overview of the complications induced by levodopa of Parkinson’s disease. Stroke Neurol Dis 24(6):571–573

19.

Xiao W, Jingjing Z (2020) Research progress on estrogen and cognitive impairment-dementia. Neurol Dis Mental Health 20(7):490–493

20.

Warren OC, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28(8):1064–1071. https://doi.org/10.1002/mds.25364CrossRef

21.

Tu Li (2017) Analysis of clinical characteristics of patients with Parkinson’s disease. Guizhou Medical University

22.

Pilleri M, Antonini A (2015) Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease. Expert Opin Drug Saf 14(2):281–294. https://doi.org/10.1517/14740338.2015.988137CrossRefPubMed

Title: Risk factors for motor complications in female patients with Parkinson’s disease
Authors: Zhirong Wan
Xuemei Wang
Huizi Ma
Zhan Wang
Tao Feng
Publication date: 06-04-2022
Publisher: Springer International Publishing
Keywords: Parkinson's Disease
Levodopa
Published in: Neurological Sciences / Issue 8/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-05959-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Risk factors for motor complications in female patients with Parkinson’s disease

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2022

Autonomic dysfunction in non-critically ill COVID-19 patients during the acute phase of disease: an observational, cross-sectional study

5-aminolevulinic acid and sodium fluorescein in IV ventricle ependymoma surgery: preliminary experience comparing the two techniques

Changes in thumb tapping rates and central motor conduction times are associated in persons with multiple sclerosis

Shape deformations of the basal ganglia in patients with classical trigeminal neuralgia: a cross-sectional evaluation

Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study

A longitudinal study on the effects of COVID-19 pandemic on non-motor symptoms in Parkinson’s disease